ACLX News and Press, Arcellx Inc. From 04/23/24

2024-04-23 09:30:00 ET Summary Baron is an asset management firm focused on delivering growth equity investment solutions known for a long-term, fundamental, active approach to growth investing. In the quarter ended March 31, 2024, Baron Health Care Fund advanced 8.92% compared wi...

Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced that management will participate in a fireside chat at the 23rd Annual Needham Virtual Health...

Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced that management will participate in a fireside chat at the H.C. Wainwright 2nd Annual Cell Th...

2024-03-07 15:15:01 ET Morgan Stanley analyst issues OVERWEIGHT recommendation for ACLX on March 7, 2024 02:52PM ET. ACLX was trading at $71.94 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 3 - Buy reco...

Arcellx to Participate at the TD Cowen 44th Annual Health Care Conference PR Newswire REDWOOD CITY, Calif. , Feb. 29, 2024 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunot...

Arcellx Provides Fourth Quarter and Year-End 2023 Financial Results and Business Highlights PR Newswire -- Expanded strategic partnership with Kite -- -- Presented continued robust long-term responses from Phase 1 expansion trial of anito-cel (formerly CART-ddBCMA) in p...

2024-02-15 11:57:01 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Following a hot year of M&A with biotech stocks , we’ll see more of the same in 2024 as drug makers look to build their pipelines ahead of a massive patent cliff. Between n...

2024-02-04 17:16:46 ET More on Alnylam Pharmaceuticals, Fusion Pharmaceuticals, etc. Merus Stock: Rally Seems Overdone Alnylam's Huge Opportunity Merus: (Maybe) Building A Better Bispecific Regeneron eyes Wegovy combo to improve quality of weight loss ...

2024-01-30 05:13:34 ET Summary Arcellx is focused on engineering safer and more accessible cell therapies for cancer patients and those with incurable diseases. The company's lead product candidate, CART-ddBCMA, has shown potential as a game-changing strategy for the treatment of ...

2024-01-16 13:51:12 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Biotech stocks , and the sector in general, saw a widespread beat down over the past two years. Venture capital dried up, post-pandemic healthcare landscapes shifted, and regulatory clamp...